Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20699642
DOI
10.4161/cc.9.15.12521
PII: 12521
Knihovny.cz E-resources
- MeSH
- Cell Nucleus drug effects metabolism MeSH
- Transcription, Genetic drug effects MeSH
- Nuclear Proteins genetics metabolism MeSH
- Janus Kinase 1 metabolism MeSH
- Cell Compartmentation drug effects MeSH
- Humans MeSH
- RNA, Messenger genetics metabolism MeSH
- Cell Line, Tumor MeSH
- Tumor Suppressor Proteins genetics metabolism MeSH
- Tumor Suppressor Protein p53 metabolism MeSH
- Neoplasms enzymology genetics pathology MeSH
- DNA Damage drug effects MeSH
- Promyelocytic Leukemia Protein MeSH
- Antineoplastic Agents pharmacology MeSH
- Gene Expression Regulation, Leukemic drug effects MeSH
- Response Elements genetics MeSH
- Signal Transduction drug effects MeSH
- Cellular Senescence drug effects MeSH
- STAT Transcription Factors metabolism MeSH
- Transcription Factors genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Nuclear Proteins MeSH
- Janus Kinase 1 MeSH
- RNA, Messenger MeSH
- Tumor Suppressor Proteins MeSH
- Tumor Suppressor Protein p53 MeSH
- PML protein, human MeSH Browser
- Promyelocytic Leukemia Protein MeSH
- Antineoplastic Agents MeSH
- STAT Transcription Factors MeSH
- Transcription Factors MeSH
The Promyelocytic leukemia protein (PML) tumor suppressor is upregulated in several forms of cellular senescence, however the mechanism of its induction is elusive. Here we show that genotoxic drugs that induce senescence, such as 5-bromo-2'deoxyuridine (BrdU), thymidine (TMD), distamycin A (DMA), aphidicolin (APH), etoposide (ET) and camptothecin (CPT) all evoke expansion of PML nuclear compartment and its association with persistent DNA lesions in several human cancer cell lines and normal diploid fibroblasts. This phenomenon was accompanied by elevation of PML transcripts after treatment with BrdU, TMD, DMA and CPT. Chemical inhibition of all JAK kinases and RNAi-mediated knock-down of JAK1 suppressed PML expression, implicating JAK/STAT-mediated signaling in regulation of the PML gene. As PML protein stability remained unchanged after drug treatment, decreased protein turnover was unlikely to explain the senescence-associated increased abundance of PML. Furthermore, binding activity of Interferon Stimulated Response Element (ISRE) within the PML gene promoter, and suppression of reporter gene activity after deletion of ISRE from the PML promoter region suggested that drug-induced PML transcription is controlled via transcription factors interacting with this element. Collectively, our data show that upregulation of the PML tumor suppressor in cellular senescence triggered by diverse drugs including clinically used anti-cancer chemotherapeutics relies on stimulation of PML transcription by JAK/STAT-mediated signaling, possibly evoked by the autocrine/paracrine activities of senescence-associated cytokines.
References provided by Crossref.org